Merck has announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine for the prevention of shingles in immunocompromised patients.
This was a double-blind, randomized, placebo-controlled, multi-center trial to study safety, tolerance, efficacy and immunogenicity of inactivated VZV vaccine in recipients of autologous hematopoietic stem cell transplants (auto-HSCT).
In the trial, V212 met its primary endpoint and reduced the incidence of confirmed HZ cases by an estimated 64 percent in recipients of auto-HSCT.
Secondary endpoint findings from the study showed that V212 reduced the incidence of moderate-to-severe HZ pain by an estimated 69.5 percent, utilizing the Zoster Brief Pain Inventory (ZBPI) score.
These results were presented as an oral presentation at the combined annual meetings of the Center for International Blood and Marrow Transplant Research and the American Society for Blood and Marrow Transplantation during a Best Abstracts session in Orlando.
Merck releases preliminary results of shingles vaccine